AR021355A1 - DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE - Google Patents

DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE

Info

Publication number
AR021355A1
AR021355A1 ARP990105927A ARP990105927A AR021355A1 AR 021355 A1 AR021355 A1 AR 021355A1 AR P990105927 A ARP990105927 A AR P990105927A AR P990105927 A ARP990105927 A AR P990105927A AR 021355 A1 AR021355 A1 AR 021355A1
Authority
AR
Argentina
Prior art keywords
medicine
manufacture
pharmaceutical composition
derivatives
quinolina
Prior art date
Application number
ARP990105927A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Spa
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9825552.4A external-priority patent/GB9825552D0/en
Priority claimed from GBGB9825553.2A external-priority patent/GB9825553D0/en
Application filed by Smithkline Beecham Spa, Smithkline Beecham Lab filed Critical Smithkline Beecham Spa
Publication of AR021355A1 publication Critical patent/AR021355A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de quinolina que comprenden un compuesto o un solvato o una sal de éste, de formula (1) en la que Ar, R1, R2, R3, R4 y R5 tienen un significadodado en la memoria descriptiva; un procedimiento para preparar dichos compuestos, una composicion farmacéutica que comprende dichos compuestos y el uso dedichos compuestos en la fabricacion de medicamentos en condiciones primarias y secundarias en medicina.Quinoline derivatives comprising a compound or a solvate or a salt thereof, of formula (1) in which Ar, R1, R2, R3, R4 and R5 have a meaning given in the specification; a process for preparing said compounds, a pharmaceutical composition comprising said compounds and the use of said compounds in the manufacture of medicaments in primary and secondary conditions in medicine.

ARP990105927A 1998-11-20 1999-11-19 DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE AR021355A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9825552.4A GB9825552D0 (en) 1998-11-20 1998-11-20 Novel compounds
GBGB9825553.2A GB9825553D0 (en) 1998-11-20 1998-11-20 Novel Compounds

Publications (1)

Publication Number Publication Date
AR021355A1 true AR021355A1 (en) 2002-07-17

Family

ID=26314705

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990105926A AR021354A1 (en) 1998-11-20 1999-11-19 PROCEDURE FOR THE PREPARATION OF A QUINOLINE DERIVATIVE COMPOUND AND A PROCEDURE TO PREPARE A PHARMACEUTICAL COMPOSITION
ARP990105927A AR021355A1 (en) 1998-11-20 1999-11-19 DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990105926A AR021354A1 (en) 1998-11-20 1999-11-19 PROCEDURE FOR THE PREPARATION OF A QUINOLINE DERIVATIVE COMPOUND AND A PROCEDURE TO PREPARE A PHARMACEUTICAL COMPOSITION

Country Status (18)

Country Link
EP (1) EP1131295A1 (en)
JP (1) JP2002530377A (en)
KR (1) KR20010075726A (en)
CN (1) CN1406225A (en)
AR (2) AR021354A1 (en)
AU (1) AU768708B2 (en)
BR (1) BR9915475A (en)
CA (1) CA2351865A1 (en)
CO (1) CO5150149A1 (en)
HK (1) HK1041257A1 (en)
HU (1) HUP0104959A3 (en)
IL (1) IL143137A0 (en)
MX (1) MXPA01005095A (en)
NO (1) NO20012473L (en)
NZ (1) NZ511777A (en)
PL (1) PL347721A1 (en)
TR (1) TR200101412T2 (en)
WO (1) WO2000031037A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
GB0027701D0 (en) * 2000-11-13 2000-12-27 Smithkline Beecham Spa Novel compounds
JP2004517062A (en) * 2000-11-13 2004-06-10 グラクソスミスクライン・ソシエタ・ペル・アチオニ Quinoline derivatives as NK-3 and NK-2 antagonists
JP2004517082A (en) * 2000-11-28 2004-06-10 グラクソスミスクライン・ソシエタ・ペル・アチオニ Quinoline derivatives as NK-3 antagonists
AU2002221923A1 (en) * 2000-11-28 2002-06-11 Glaxosmithkline S.P.A. Novel compounds
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
EP1392687B1 (en) 2001-04-10 2017-02-01 Janssen Pharmaceuticals, Inc. 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
GB0109122D0 (en) * 2001-04-11 2001-05-30 Smithkline Beecham Spa Novel compounds
ATE313539T1 (en) * 2001-04-11 2006-01-15 Glaxosmithkline Spa QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS
MY134211A (en) * 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
AU2003244080A1 (en) * 2002-06-26 2004-01-19 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
CN100402529C (en) 2002-09-09 2008-07-16 詹森药业有限公司 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders
GB0303086D0 (en) 2003-02-11 2003-03-19 Merck Sharp & Dohme New compounds
US20070060593A1 (en) * 2003-06-25 2007-03-15 Kerns Jeffrey K 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
GB0425076D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
EP1891012A2 (en) * 2005-06-03 2008-02-27 AstraZeneca AB Quinoline derivatives as nk3 anatgonists
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
AR057130A1 (en) 2005-09-21 2007-11-14 Astrazeneca Ab ALKYL SULFOXIDE QUINOLINS AND A PHARMACEUTICAL COMPOSITION
WO2007039123A2 (en) * 2005-09-22 2007-04-12 Smithkline Beecham Corporation Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
US20090325992A1 (en) * 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
JP5727139B2 (en) 2006-11-28 2015-06-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 3- (3-Amino-2- (R) -hydroxy-propyl) -1- (4-fluoro-phenyl) -8- (8-methyl-naphthalen-1-ylmethyl) -1,3,8-triaza- Spiro [4.5] decan-4-one salt
WO2008097976A1 (en) * 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
CN101679430B (en) 2007-04-09 2013-12-25 詹森药业有限公司 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of ORL-i receptor for treatment of anxiety and depression
ES2561674T3 (en) * 2010-03-23 2016-02-29 Glaxosmithkline Llc TRPV4 antagonists
BR112015026519A2 (en) 2013-04-19 2017-07-25 Astrazeneca Ab nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (sop)
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2191352C (en) * 1994-05-27 2001-01-30 Carlo Farina Quinoline derivatives as tachykinin nk3 receptor antagonists
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
WO1998052942A1 (en) * 1997-05-23 1998-11-26 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists

Also Published As

Publication number Publication date
AU1777000A (en) 2000-06-13
WO2000031037A1 (en) 2000-06-02
CO5150149A1 (en) 2002-04-29
AU768708B2 (en) 2004-01-08
PL347721A1 (en) 2002-04-22
IL143137A0 (en) 2002-04-21
NO20012473D0 (en) 2001-05-18
BR9915475A (en) 2001-12-18
KR20010075726A (en) 2001-08-09
MXPA01005095A (en) 2002-04-24
NO20012473L (en) 2001-07-18
HUP0104959A2 (en) 2002-04-29
HUP0104959A3 (en) 2003-01-28
JP2002530377A (en) 2002-09-17
EP1131295A1 (en) 2001-09-12
AR021354A1 (en) 2002-07-17
HK1041257A1 (en) 2002-07-05
CA2351865A1 (en) 2000-06-02
NZ511777A (en) 2003-12-19
CN1406225A (en) 2003-03-26
TR200101412T2 (en) 2001-10-22

Similar Documents

Publication Publication Date Title
AR021355A1 (en) DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE
ATE316083T1 (en) ADAMANTANDE DERIVATIVES
SE9904505D0 (en) Novel compounds
BRPI0215312B8 (en) compound, use of a compound, pharmaceutical composition, and process for preparing a compound
ES2079719T3 (en) DERIVATIVES OF AMIDINOPHENYLALANINE, PROCEDURE FOR ITS PREPARATION, ITS USE AND AGENTS THAT CONTAIN THEM AS ANTICOAGULANTS.
ES2157993T3 (en) BENZOILGUANIDINAS, ITS PREPARATION AND ITS USE IN MEDICINES.
ES2058527T3 (en) CONDENSED DERIVATIVES OF PIRIMIDINE PROCEDURE AND INTERMEDIATE COMPOUNDS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
NO20085077L (en) New connections
BR9303993A (en) Compound, process for preparing the same and pharmaceutical composition
UY24555A1 (en) NEW COMPOUNDS
BRPI0015567B8 (en) compound, pharmaceutical composition, dosage unit form, use of the pharmaceutical composition and method for preparing a pharmaceutical composition
AR030857A1 (en) NITROUS DERIVATIVES OF DIFENOLAMINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINAL PRODUCTS
BR9104533A (en) ANTIMICROBIAL COMPOSITION, DERIVATIVES, PROCESS FOR ITS PREPARATION, MEDICINES, PESTICIDE COMPOSITIONS, USE OF DERIVATIVES, PROCESSES FOR COMBATING PEST AND PREPARING COMPOSITIONS
ES2074846T3 (en) NEW NAFTIL-ETIL-UREAS AND NAFTIL-ETIL-TIOUREAS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ECSP003792A (en) CRYSTAL OF 4-CARBOXAMINO-1,2,3,4-TETRAHYDROQUINOLINE 2-REPLACED
AR019496A1 (en) AZALIDAS OF 13 MEMBERS, PHARMACEUTICAL COMPOSITIONS, USE IN THE PREPARATION OF MEDICINES AND PREPARATION OF THE SAME
GB0109122D0 (en) Novel compounds
ES2122637T3 (en) DERIVATIVES OF THIAZOLIDINE, ITS PREPARATION AND THE MEDICINES THAT CONTAIN THEM.
ES2052028T3 (en) A METHOD FOR PREPARING ANTI-ATEROSCLEROTIC DIARILIC COMPOUNDS.
NO304113B1 (en) Crystalline thiagabine hydrochloride monohydrate, pharmaceutical composition comprising it, and use thereof for the manufacture of a medicament
NO922380L (en) SUBSTITUTED 4-PHENYL-4-PIPERIDINE CARBOXAMIDS WITH BOTH LOCAL ANESTHETIC AND ANALGETIC EFFECT AND PROCEDURES FOR THEIR PREPARATION
ES2111871T3 (en) NEW AMINO ACID DERIVATIVES, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
MX9400165A (en) DERIVATIVES OF TER-BUTYLERGOLINE, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
AR002017A1 (en) DERIVATIVES OF FENIL-4-TIAZOLES SUBSTITUTED, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND DERIVATIVES DEFENIL-4-TIAZOLES SUBSTITUTED USED IN SUCH PROCEDURE.
ES2039292T3 (en) DERIVATIVES OF PYRANOBENZOXADIAZOLE, PREPARATION OF THE SAME, USE AND COMPOUNDS THAT INCLUDE THEM.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal